Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort

키워드

참고문헌 (31)

1. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American association for the study of liver diseases", Hepatology, 67, pp.328~357 (2018)
2. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755.e3 (2019)
3. Sookoian S, "Genetic predisposition in nonalcoholic fatty liver disease", Clin Mol Hepatol, 23, pp.1~12 (2017)
4. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
5. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
6. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
7. Pirola CJ, "Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease", J Lipid Res, 60, pp.176~185 (2019)
8. Ma Y, "17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease", Hepatology, 69, pp.1504~1519 (2019)
9. Gellert-Kristensen H, "High risk of fatty liver disease amplifies the alanine transaminaselowering effect of a HSD17B13 variant", Hepatology, 71, pp.56~66 (2020)
10. Seko Y, "Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13in Japanese patients with non-alcoholic fatty liver disease", Liver Int, 40, pp.1686~1692 (2020)
11. World Health Organization, "The Asia-Pacific perspective : redefining obesity and its treatment" (2000), Health Communications Australia
12. Expert Panel on Detection, "Executive summary of the third report of the national cholesterol education program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
13. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
14. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
15. Gauderman WJ, "Sample size requirements for matched case-control studies of gene-environment interaction", Stat Med, 21, pp.35~50 (2002)
16. Goh SC, "Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia", Hepatol Int, 7, pp.548~554 (2013)
17. Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
18. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
19. Chan WK, "Non-alcoholic fatty liver disease in a young multiracial Asian population : a worrying ethnic predilection in Malay and Indian males", Hepatol Int, 8, pp.121~127 (2014)
20. Zain SM, "A multi-ethnic study of a PNPLA3 gene variant and its associa tion with disease severity in non-alcoholic fatty liver disease", Hum Genet, 131, pp.1145~1152 (2012)
21. Younossi Z, "Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 15, pp.11~20 (2018)
22. Horiguchi Y, "17 beta-Hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein", Biochem Biophys Res Commun, 370, pp.235~238 (2008)
23. Su W, "Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease", Proc Natl Acad Sci U S A, 111, pp.11437~11442 (2014)
24. Su W, "Role of HSD17B13 in the liver physiology and pathophysiology", Mol Cell Endocrinol, 489, pp.119~125 (2019)
25. Wang P, "HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease : a systematic review and meta-analysis", Eur Rev Med Pharmacol Sci, 24, pp.8997~9007 (2020)
26. Scheiner B, "Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension", Liver Int, 40, pp.393~404 (2020)
27. Haring R, "Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels", Hepatology, 50, pp.1403~1411 (2009)
28. Ruhl CE, "Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population", Gastroenterology, 136, pp.477~485.e11 (2009)
29. Fujii H, "Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver : a retrospective cohort study", BMC Gastroenterol, 20, pp.217~ (2020)
30. Herskowitz I, "Functional inactivation of genes by dominant negative mutations", Nature, 329, pp.219~222 (1987)
31. Strachan TR, "Human Molecular Genetics" (2011), Garland Science Taylor and Francis Group

관련 논문AI추천